Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AM-1638 is a full agonist of GPR40/FFA1 (EC50: 0.16 μM).
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約8-10 週間 | ¥ 205,000 |
50 mg | 約8-10 週間 | ¥ 266,500 |
100 mg | 約8-10 週間 | ¥ 399,500 |
ターゲット&IC50 | FFA1/GPR40:0.16 μM |
In vivo | AM-1638 demonstrates moderate cross-species plasma clearance and distribution volume, leading to plasma half-lives conducive to the assessment of its antidiabetic effects in mice, rats, and cynomolgus monkeys. It shows antidiabetic activity in BDF/DIO mice[1]. Furthermore, the oral administration of the full agonist AM-1638 reveals superb oral bioavailability, exceeding 100% in mice, and achieving 72% and 71% in rats and cynomolgus monkeys, respectively. |
分子量 | 514.63 |
分子式 | C33H35FO4 |
CAS No. | 1142214-62-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 250 mg/mL (485.79 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
AM-1638 1142214-62-7 Endocrinology/Hormones GPCR/G Protein GPR AM1638 AM 1638 Inhibitor inhibitor inhibit